Citations

Clear

1707 citation(s) found for "He, Philip".

Quality Measures Addressing Disparities to Improve Outcomes in Hand Surgery
Schultz, Emily , Richard, Marc J. , Ruch, David S. , Ring, David , Kakar, Sanjeev , Got, Christopher, Akelman, Edward , Blazar, Philip E., Yao, Jeffrey, Sears, Erika D. , Schultz, Emily A , Ring, David , Kakar, Sanjeev , Sears, Erika D , Kamal, Robin N , Shapiro, Lauren M , Snyder, Eli M. , Richard, Marc J., Got, Christopher , Blazar, Philip , Yao, Jeffrey , Ladd, Amy L. , Kamal, Robin N.

Mayo Clinic

HAND | June 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15589447261453556 | PMID 42337843 Get It

Background: There is growing evidence that social determinants of health (SDOH) are associated with disparities in access to care and hand and upper extremity health. Quality measures represent an opportunity to evaluate disparities in access and outcomes that can inform improvement interventions. We performed a systematic review of evidence regarding health disparities within hand surgery and aimed to develop suitable quality measures that are clinically important, feasible, usable, and scientifically acceptable. Methods: We performed a systematic review including common hand surgery terms to identify health disparities in hand surgery related to SDOH. Candidate quality measures were constructed based upon evidence from the systematic review. A consortium of 11 US-based hand and upper extremity surgeons completed a modified RAND/UCLA Delphi Appropriateness process to evaluate the importance, feasibility, usability, and scientific acceptability of the candidate quality measures. Panelists rated each measure on a scale of 1 ( definitely not important/feasible/usable/scientifically acceptable ) to 9 ( definitely important/feasible/usable/scientifically acceptable ) in 2 voting rounds separated by a face-to-face discussion. Agreement among panelists and validity were assessed using predetermined criteria. Results: Fourteen candidate quality measures addressing health disparities were identified based on evidence from the systematic review, including time to surgery and emergency department use after hand surgery based on insurance type, clinical outcomes based on social deprivation, among others. All 14 measures were accepted. Conclusions: Fourteen candidate quality measures were identified and accepted based upon consensus to address health disparities in hand surgery, although future investigation will be needed to evaluate their effectiveness.
Combining post-mortem and neuroimaging measures of brain amyloidosis to accelerate genomic discovery
Wang, Ting‐Chen , Ali, Muhammad, Wu, Yiyang , Mormino, Elizabeth, Buckley, Rachel F. , Saykin, Andrew J, Jager, Philip L. De , Schneider, Julie A, Vardarajan, Badri, Mayeux, Richard, Kunkle, Brian W, Keene, C Dirk, Seshadri, S, Sperling, Reisa A, Kamboh, M Ilyas, Jagust, William J. , Schellenberg, Gerard D, Huentelman, MJ, Hamilton-Nelson, Kara, Pericak-Vance, Margaret A, Haines, Jonathan L, Montine, Thomas J, Beecham, Gary, Archer, Derek , Wu, Yiyang , Buckley, Rachel F , De Jager, Philip L , Bennett, David A. , Barnes, Lisa L , Bush, William S , Vemuri, Prashanthi , Ramanan, Vijay K , Harrison, Theresa M , Jagust, William J , Laws, Simon M , Below, Jennifer E , Cruchaga, Carlos , Seto, Mabel , Dumitrescu, Logan , Archer, Derek B. , Ali, Muhammad , Mormino, Elizabeth C. , Lee, Annie , Saykin, Andrew J. , Schneider, Julie A. , Bennett, David A. , Barnes, Lisa L. , Vardarajan, Badri Narayan , Mayeux, Richard , Kunkle, Brian W. , Bush, William S. , Keene, C Dirk, Sperling, Reisa Anne , Vemuri, Prashanthi , Ramanan, Vijay K. , Kamboh, M. Ilyas , Harrison, Theresa M. , Schellenberg, Gerard D. , Hamilton‐Nelson, Kara L. , Pericak‐Vance, Margaret A. , Goate, Alison , Haines, Jonathan L. , Montine, Thomas J. , Beecham, Gary W. , Hohman, Timothy J. , Dumitrescu, Logan

Mayo Clinic

Brain | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag216 | PMID 42334898 Get It

Abstract Histopathological assessment has served as the gold standard for diagnosing Alzheimer’s disease (AD). Emerging technological advancements, including the development of amyloid positron emission tomography (PET), have enabled early detection of amyloid pathology, one of the neuropathological hallmarks of AD. Genome-wide association study (GWAS) across cohorts of aging and AD, leveraging different measurements of amyloid burden, may facilitate the identification of novel genetic variants that drive the earliest neuropathological changes in AD. This study presents the largest GWAS of brain amyloidosis to date, leveraging amyloid β (Aβ) measured by in vivo amyloid PET and postmortem histopathology from 13,555 individuals of European ancestry. Amyloid positivity was defined as moderate or frequent neuritic plaques according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) staging scores for each postmortem cohort. A Gaussian mixture model (GMM) was applied to each amyloid PET cohort to identify the cohort and tracer-specific cut-offs that differentiate amyloid positive and negative populations. In silico and ex vivo analyses further characterized implicated loci, including interrogating the association between bulk and single-nucleus gene expression profiles and AD-related traits. Genetic covariance analysis assessed the extent amyloid PET and postmortem measures reflect the shared genetic architecture of brain amyloidosis. Our combined amyloidosis GWAS identified three established AD risk loci: BIN1 (rs6733839, OR = 1.20, 95% CI 1.14-1.26, P = 1.32 × 10−11), CR1 (rs4844610, OR = 1.24, 95% CI = 1.16-1.32, P = 4.21 × 10−10), APOE (rs429358, OR = 4.01, 95% CI = 3.66-4.38, P = 4.54 × 10−201), and a newly identified brain amyloidosis-associated variant on chromosome 17 (rs35635959, OR = 1.18, 95% CI = 1.12-1.25, P = 1.47 × 10−8). SuSiE fine-mapping identified a single credible set of 15 putative causal variants with rs35635959 as the lead variant. Subsequent eQTL and SuSiE-based colocalization analyses prioritized rs35635959 as a strong eQTL for TUBG2, encoding tubulin gamma 2, which is involved in microtubule organization and synaptic plasticity. Further cell-type-specific characterization of this gene in neurons from dorsolateral prefrontal cortex tissue indicated that decreased TUBG2 expression was associated with increased Aβ burden and AD case status (PFDR < 0.045). Furthermore, our study is the first to report a modest genetic covariance (covariance=0.17, P < 6.54 × 10−8) between the genetic architecture of amyloid burden captured by different modalities. While APOE showed a strong association with both amyloid endophenotypes, the observed genetic covariance was not substantially attenuated after excluding variants within the APOE region (covariance=0.16, P < 1.32 × 10−7). Our results highlight the benefits of leveraging compatible, harmonized AD endophenotypes to increase power to uncover new molecular insights into the etiology of AD neuropathology. Wang et al. present the largest GWAS of brain amyloidosis to date, analysing 13,555 individuals using amyloid PET and postmortem Aβ measures. They identify a novel amyloidosis-associated variant on chromosome 17, demonstrate genetic covariance between modalities, and highlight complex traits sharing genetic architecture with Aβ burden.
Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia
Olzinski, Molly, Downer, Joshua, Rajbanshi, Binita, Li, Jingyao, Loureiro, Joseph, Heuer, Hilary, Ljubenkov, Peter, Vandevrede, Lawren, Staffaroni, Adam, Lario‐Lago, Argentina, Leichter, Dana, Wolf, Amy, Wise, Amy, Sanderson-Cimino, Mark, Barragan, Eden, Spina, S, Grinberg, Lea T., Seeley, William W., Casaletto, Kaitlin B., Kramer, Joel, Ramos, Eilana, Geschwind, Daniel, Cook, Casey, Petrucelli, L, Forsberg, Leah K., Gendron, Tania, Boeve, Bradley F., Rademakers, Rosa, Rosen, Howard J., Saloner, Rowan, Boxer, Adam L., Rojas, Julio C., Abdullah, M. Samy, Apostolova, Liana, Appleby, Brian, Bayram, Ece, Hp, Botha, Bozoki, Andrea, Brushaber, Danielle, Clark, David, Considine, Ciaran M., Darby, R. Ryan, Day, Gregory S., Dickerson, Bradford C., Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily, Faber, Kelley M., Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana, Galasko, Douglas R., Gavrilova, Ralitza, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Cn, Hales, Honig, Lawrence S., Gd, Hsiung, Huey, Edward D, Irwin, David, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler , Kornak, J M, Kremers, W., Kwan, Justin , Lapid, Maria, Lee, Suzee, Litvan, Irene, Lucente, Diane, Mackenzie, Ian R., Masdeu, J C, Massimo, Lauren, McGinnis, Scott, McMillan, Corey T., Mendez, Mario F., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pantelyat, Alexander, Pascual, Belen, Paulson, Henry, Ramanan, Vijay, Rankin, Katherine P., Rascovsky, Katya, Rhoads, Kristoffer , Savica, Rodolfo, Snyder, Allison, Sullivan, A. Campbell, Syrjanen, Jeremy, Tartaglia, M, Taylor, Jack, Tipton, P E, WEINTRAUB, S, Wint, Dylan, Wong, Bonnie, Yokoyama, Jennifer, Paulson, Henry L. , Barmada, Sami J. , Paulson, Henry L , Barmada, Sami , Cobigo, Yann , Worringer, Kathleen A. , Heuer, Hilary W. , VandeVrede, Lawren , Staffaroni, Adam M. , Wolf, Amy , Wise, Amy B. , Sanderson‐Cimino, Mark , Barragan, Eden V. , Grinberg, Lea T. , Seeley, William W. , Casaletto, Kaitlin B. , Kramer, Joel, Ramos, Eliana Marisa , Geschwind, Daniel H. , Forsberg, Leah K. , Gendron, Tania F. , Boeve, Bradley F. , Perneel, Jolien , Rademakers, Rosa , Rosen, Howard J. , Saloner, Rowan , Boxer, Adam L. , Rojas, Julio C. , Appleby, Brian S. , Barmada, Sami, Bayram, Ece , Botha, Hugo, Bozoki, Andrea C , Brushaber, Danielle , Clark, David, Considine, Ciaran , Dickerson, Bradford Clark , Dickson, Dennis, Domoto‐Reilly, Kimiko , Dwosh, Emily , Foroud, Tatiana, Graff‐Radford, Jonathan , Graff-Radford, Neill, Hales, Chadwick M., Honig, Lawrence S. , Hsiung, Ging-Yuek R., Huey, Edward D. , Jones, David T., Kantarci, Kejal , Kornak, John , Kremers, Walter, Kwan, Justin, Léger, Gabriel C. , Litvan, Irene , Lucente, Diane , Mackenzie, Ian R. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T. , Mendez, Mario F. , Mester, Carly , Pascual, Belén , Ramanan, Vijay, Rankin, Katherine P. , Roberson, Erik D. , Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Syrjanen, Jeremy A. , Taylor, Jack C. , Tipton, Philip W., Vandebergh, Marijne , Weıntraub, Sandra , Wint, Dylan

Mayo Clinic

JAMA Neurology | June 22, 2026 | Volume: 83 | Issue: 8 | Pages: 778

10.1001/jamaneurol.2026.1927 | PMID 42329632 Get It

Importance TMEM106B is a frontotemporal lobar degeneration (FTLD) genetic susceptibility factor, and TMEM106B protein aggregates are a feature of aging and neurodegeneration. Whether TMEM106B protein levels are associated with clinical features is unknown. Objective To investigate the clinical associations of cerebrospinal fluid (CSF) TMEM106B in FTLD. Design, Setting, and Participants This cross-sectional study was conducted in 2 independent frontotemporal dementia (FTD) cohorts (recruitment from April 2009 through July 2023, with analyses from January 2025 through April 2026), with a 2-year follow up. This multicenter clinical study integrated clinical, genetic, biomarker, and neuroimaging data. Individuals were recruited through the University of California, San Francisco (n = 3733), or ALLFTD (n = 2343). Participants with available CSF were included. A discovery cohort (n = 271) included participants with sporadic neuropathology-confirmed FTLD; presymptomatic or symptomatic carriers of pathogenic variants in C9orf72 , GRN , or MAPT ; or controls. An independent validation cohort (n = 383) included participants with clinically diagnosed sporadic FTD, Alzheimer disease (AD), and controls. Exposures CSF samples for TMEM106B quantification with aptamer proteomics (SomaScan version 3.0 [discovery cohort] and SomaScan version 4.1 [validation cohort]). Main Outcomes and Measures Parametric tests compared the primary outcome, CSF TMEM106B, by disease severity, TMEM106B rs1990622 genotype, sex, clinical syndrome, pathological diagnosis, and pathogenic variant and determined associations with brain volume. Results In the discovery (n = 271; 136 women [51%]; median [IQR] age, 59 [38-80] years) and validation (n = 383; 183 women [48%]; median [IQR] age, 64 [50-78] years) cohorts, lower CSF TMEM106B was associated with more severe disease (β, −0.15; 95% CI, −0.24 to −0.04; P = .003), lower frontotemporal brain volumes (β, 0.42; 95% CI, 0.24-0.61; P < .001), and faster clinical progression (β, −2.21; 95% CI, −3.70 to −0.72; P = .001). Associations of TMEM106B with clinical disease severity were independent of those with neurofilament light chain. TMEM106B levels were influenced by TMEM106B rs1990622 genotype, where individuals with the protective G/G genotype had lower levels than the risk A/A genotype. CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD. Conclusions and Relevance Per the results of this cross-sectional study, TMEM106B is detectable in CSF and levels reflect disease severity in sporadic and genetic FTLD and AD, but levels are also influenced by the TMEM106B rs1990622 genotype. CSF TMEM106B could support further studies to understand the mechanisms of disease and develop clinical tools in FTLD and other neurodegenerative diseases.
Learning Curves and Complexity Evolution in Robotic Liver Surgery
Kuemmerli, Christoph , Hess, Gabriel Fridolin , Billeter, Adrian T. , Benedetto, Fabrizio Di , Odorizzi, Roberta, Sucandy, Iswanto , Aegerter, Noa L. E., Berchtold, Caroline , Bernardi, L. , Cristaudi, Alessandra , Balzano, E , Koh, Ye-Xin, Lin, Charles Chung-Wei, Fukumori, Daisuke , Tschuor, Christoph , White, Steve, Kroge, P Von, Heumann, Asmus , Meyere, Céline De, D’hondt, M, Haak, Fabian, Stättner, Stefan, Primavesi, Florian, Morgül, Haluk , Andreou, A, Ratti, F, Esquer, Ignacio Sánchez, Robles-Campos, Ricardo, Lopez-Lopez, Victor, Wakabayashi, Go , Nebbia, Martina, Rahbari, Nuh N., Ferretti, Stefano, Ettore, Giuseppe , Croner, RS , Dong, Y, Starlinger, P, Nickel, F, Müller, Beat P., Hess, Gabriel F , Guidetti, Cristiano , di Benedetto, Fabrizio , Sucandy, Iswanto , Aegerter, Noa L E , Berchtold, Caroline , Bernardi, Lorenzo , Cristaudi, Alessandra , Balzano, Emanuele , Ghinolfi, Davide , Goh, Brian K P , Fukumori, Daisuke , Tschuor, Christoph , Pandanaboyana, Sanjay , De Meyere, Celine , Seehofer, Daniel , Esquer, Ignacio Sánchez , Müller, Philip C , Koh, Ye-Xin , Lin, Charles Chung-Wei, Tschuor, Christoph , Kroge, Philipp H. von , D’Hondt, Mathieu , Haak, Fabian , Stättner, Stefan , Primavesi, Florian , Ratti, Francesca , Robles-Campos, Ricardo, López‐López, Víctor , Wakabayashi, Taiga , Nebbia, Martina , Gilg, Stefan , Birgin, Emrullah , Ferretti, Stefano , Ettore, Giuseppe Maria, Rahimli, Mirhasan , Nickel, Felix , Müller-Stich, Beat Peter

Mayo Clinic

Annals of Surgery | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007123 | PMID 42307103 Get It

Objective: To evaluate the institutional learning curve of robotic liver resection (RLR), its association with surgical complexity and outcomes in an international multicenter cohort. Summary of Background Data: RLR is increasingly adopted worldwide, but the dynamics of the learning process and its impact on surgical outcomes remain poorly defined. Methods: This international, multicenter, retrospective cohort study included consecutive patients who underwent RLR between 06/2013 and 12/2024 across 22 expert centers. Based on the first 150 cases at each center, three phases were used to define the learning curve: operative time for competency, major complications for proficiency, and textbook outcome for mastery. Risk-adjusted generalized additive models were used to assess the learning process. Benchmark performance was compared to international reference values. Results: Among 2,331 patients, the most common indications were hepatocellular carcinoma (36%), benign lesions (23%) and colorectal liver metastases (21%). Operative time decreased after achieving competency (case #62), from 240 to 220 minutes ( P <0.001). Major morbidity reached a plateau during the proficiency phase (cases #63–138; 9% vs. 11%, P =0.144), while progression to mastery (cases #139–150) was associated with a higher rate of textbook outcome (76% vs. 87%, P =0.021). In contrast, conversion (5.1% vs. 4.9% vs. 2%), bile leak (4.0% vs. 5.3% vs. 3.8%), and 90-day mortality (0.7% vs. 0.9% vs. 0.9%) remained low and stable across all learning phases. Importantly, benchmark criteria for operative time, hospital stay, and textbook outcome were met across all complexity groups, including during the early learning phase. Conclusions: Robotic liver surgery shows progressive outcome improvement with early achievement of benchmark-level results and stable performance across increasing complexity. These findings indicate that, in experienced centers, RLR can be safely implemented and integrated into clinical practice, supporting its key role in modern hepatobiliary surgery.
Cardiac magnetic resonance imaging parameters predict new-onset symptoms of heart failure in hypertrophic cardiomyopathy
Silva, Danuzia Santana da, Vizentin, Vanessa Karlinski , Maanja, Maren , Lahori, Simmy A, Ommen, Steve, Geske, Jeffrey B, Giudicessi, John R, Araoz, Philip A. , Ackerman, Michael J, Arruda‐Olson, Adelaide M. , Bos, J. Martijn , da Silva, Danuzia S, Félix, Iuri Ferreira , Bos, Johan M , Lahori, Simmy , Pasupathy, Kalyan S. , Ommen, Steve R. , Geske, Jeffrey B. , Giudicessi, John R. , Ackerman, Michael J.

Mayo Clinic

ESC Heart Failure | June 6, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/eschf/xvag160 | PMID 42263198 Get It

Abstract Background Hypertrophic cardiomyopathy (HCM) is a heritable cardiac disorder characterized by increased left ventricular (LV) wall thickness, often leading to heart failure (HF). The role of cardiovascular magnetic resonance (CMR) imaging in predicting new onset of HF symptoms in patients with HCM remains unknown. This study aimed to identify CMR predictors of new-onset HF symptoms in individuals with HCM. Methods This study was a single-centre retrospective cohort study of HCM patients treated at a tertiary referral centre in the USA who underwent CMR examination between 1998 and 2018, had no HF symptoms at baseline CMR, and at least 1 year of follow-up. Clinical data were collected by review of electronic medical records, and CMR images were analyzed by a blinded expert cardiac radiologis. The primary outcome was new onset of HF symptoms, defined as New York Heart Association (NYHA) class ≥ II at follow-up. Kaplan–Meier analyses and Cox proportional hazard analyses were performed. Results Of 1462 patients diagnosed with HCM who had at least 1 CMR, 276 HCM patients without HF symptoms (average age 52.7 years, 33.3% female),median maximum left ventricular (LV) wall thickness was 19 mm ([IQR] 17–22) with a and median LV ejection fraction of 71% (IQR 66–77). Late gadolinium enhancement was detected in 56.2%) patients (60.7% had mild; 30.7% moderate; 8.6% severe). During a median follow-up period of 6.3 years, 93 patients developed HF symptoms (NYHA class II in 56 (60.2%); class III in 31 (33.3%); and class IV in 6 (6.5%). Multivariable analysis adjusted for age showed that LA enlargement (HR 1.626; 95% CI 1.01–2.62; P = .045) and LV mass index (HR 1.014; 95% CI 1.007–1.022; P≤ .001) and sex (HR 1.7; 95% CI 1.074–2.691; P = .023) were independent predictors of new onset of HF symptoms in patients with HCM. Conclusions Nearly half of the patients with HCM developed HF symptoms within 6.3 years. Left atrial enlargement, LV mass index, and sex were independent predictors of new onset of HF symptoms in HCM patients. These findings emphasize the value of CMR in HF risk stratification.
OC.57 Safety and efficacy of CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, in systemic sclerosis (SSc): findings from the breakfree-1 trial
Khanna, D, Korman, David S., Mease, Philip, Griffith, Melissa, Carpintero, Maria , Wener, Mark H. , Kramer, Neil , Schett, G, Mayes, Maureen D., Melton, Alexis, Handy, Whitney, Ou, San-San, Jarugula, Praneeth , Ide, Takafumi , Harnois, Melissa, Thorpe, Jerill , Koegel, Ashley, Wiesendanger, Margrit, Harnois, Melissa J. , Khanna, Dinesh , Majithia, Vikas , Bernstein, Elana J. , Mease, Philip J. , Simon, David , Schett, Georg , Gómez‐García, Ignacio , Mayes, Maureen D. , Desai, Alisha, Handy, Whitney, Ou, San‐San , Ide, Takafumi, Koegel, Ashley K., Wiesendanger, Margrit

Mayo Clinic

Oral Communications | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: A61-A63

10.1136/jsrd-2026-sswc.57 Get It

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
Dasari, Arvind, Yu, Guan, Kopetz, Scott, Puhalla, Shannon L., Lucas, Peter C., Sahin, Ibrahim Halil, Deming, Dustin A. , Philip, Philip Agop, Hong, Theodore S., Rojas-Khalil, Yesenia, Loree, J M, George, Thomas J., Lieu, Christopher, Dasari, Arvind , Yu, Guan, Kopetz, Scott , Puhalla, Shannon L. , Sahin, Ibrahim Halil, Philip, Philip Agop, Rojas-Khalil, Yesenia, Loree, Jonathan M. , Wolmark, Norman , Yothers, Greg , George, Thomas J.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps3686 Get It

TPS3686 Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer (CC) to determine need for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and may outperform traditional clinical and pathological features in prognosticating risk for recurrence. CC pts who do not have detectable ctDNA (ctDNA–) are at a much lower risk of recurrence and may be spared the toxicities associated with AC. Furthermore, for CC pts with detectable ctDNA (ctDNA+) who are at a very high risk of recurrence, the optimal AC regimen has not been established. We hypothesize that for pts whose CC has been resected, ctDNA status may be used to risk-stratify for making decisions about AC. Methods: In this prospective phase II/III trial, up to 1,912 pts with resected stage IIB, IIC, and III CC will be enrolled. Based on the post-operative ctDNA status using personalized and tumor-informed assay (Signatera, bespoke assay), those who are ctDNA– (Cohort A) will be randomized to immediate AC with fluoropyrimidine (FP)+oxaliplatin (Ox) for 3-6 mos per established guidelines v serial ctDNA monitoring. Patients who are ctDNA+ post-operatively, or with serial monitoring (Cohort B), will be randomized to FP+Ox v more intensive AC with addition of irinotecan (I) for 6 mos. One cycle of chemotherapy is allowed while awaiting ctDNA testing results for cohort assignment. The primary endpoints for Cohort A are time to ctDNA+ status (phase II) and disease-free survival (DFS) (phase III) in the immediate v delayed AC arms. The primary endpoint for Cohort B is DFS in the FP+Ox v FP+Ox+I arms for both phase II and phase III portions of the trial. Secondary endpoints include prevalence of detectable ctDNA post-operatively, time-to-event outcomes (overall survival and time to recurrence) by ctDNA status, and the assessment of compliance to adjuvant therapy. Biospecimens including archival tumor tissue, as well as post-operative plus serial matched/normal blood samples, will be collected for exploratory correlative research. Active enrollment across the NCTN started in June 2022 with CCTG sites joining in August 2023. Accrual is 1,123/1,912 (as of 1/20/2026). *Drs. Dasari and Lieu contributed equally to the development of this trial. Clinical trial information: NCT05174169 .
CAMPERR: A multicenter, prospective, observational study to evaluate a cfDNA-based genome-wide methylation enrichment assay for multicancer early detection (MCED), identification of molecular residual disease, and relapse prognostication.
Idos, Gregory, Holmes, Faith L., Boardman, Lisa A., Mazzone, Peter J. , Nabavizadeh, Nima , Lammers, Phil, Ahluwalia, M., Padmanabhan, Arvinda, Burkeen, Christopher Grant, Nash, Charles H., Clyburn-Ipock, Virginia L., Okeke, Ifeoma Roseline, Byrnes, Abigail B., Silvestri, Gerard A., Anderson, Michelle H., Landers, Kaytlin, Provance, Jeremy , Sosa, Eduardo V., Allen, Brian, Rini, Brian I., Idos, Gregory , Boardman, Lisa A., Lammers, Philip E. , Ahluwalia, Manmeet S. , Burkeen, Christopher G. , Silvestri, Gerard A. , Allen, Brian, Rini, Brian I.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps10628 Get It

TPS10628 Background: Despite advances in cancer treatment, a lack of established population-level cancer screening strategies for early detection across cancer types contributes to cancer-related mortality. Emerging MCED liquid biopsy tests represent a screening approach with potential to enable detection of multiple malignancies at earlier stages in the disease process. We previously showed that an initial classifier based on a genome-wide methylome enrichment platform detected 12 cancer types, including early-stage, low-shedding tumors (Park et al. AACR 2023. Abs 1030). However, clinical performance of the platform has not been evaluated prospectively. Thus, the CAMPERR study (NCT05366881) was designed to train and validate a cell-free methylated DNA immunoprecipitation and high throughput sequencing (cfMeDIP-seq)-based test for detection and differentiation of 20 pre-selected cancer types, representing 93% of annual cancer incidence and 88% of annual cancer deaths. Longitudinal follow-up for a subset of participants with lung cancer will enable training and validation for MRD-based recurrence prognostication. Methods: This case-control study is enrolling participants with 20 different pre-specified cancer types (n=2400) and those without known cancer (n=3900). Eligible participants are ≥40 years of age and not receiving treatment for cancer at the time of enrollment or taking any demethylating/hypomethylating agents. Cases include individuals with newly diagnosed (≤120 days), untreated cancer or recurrence of a cancer originally diagnosed >5 years ago. Cancers of interest are stage I-IV bladder, brain, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. Participants with stage I-III lung cancer will have clinical follow-up and blood draws after completion of first-line treatment, every 3 mo for the first year thereafter, and every 6 mo for an additional 2 years. Eligible control participants have not been diagnosed with invasive cancer in the last 5 years and will have clinical follow-up ≥12 mo from enrollment to evaluate cancer status. Liquid biopsy results will not be returned to clinicians or participants. The primary objective is cancer detection. Secondary objectives include detection of specific cancer types, identification of the tissue of origin, and prognostication of clinical outcomes (eg, recurrence-free survival, overall survival). CAMPERR is currently enrolling at 15 sites. As of December 3, 2025, 2108 of 2400 cancer cases have been enrolled, including prostate (n=225), lung (n=216), colorectal (n=211), breast (n=193), and pancreatic (n=192); controls are fully enrolled. Clinical trial information: NCT05366881 .
Coronary Artery Proximity to Potential Ablation Sites in Children: The Case for Careful Consideration
Magnan, Rachel A., Qureshi, MYasir, Asztalos, Ivor , Wackel, Philip L. , Qureshi, Muhammad Yasir, Taggart, Nathaniel W , Wackel, Philip , Qureshi, Yasir M., Asztalos, Ivor , Taggart, Nathaniel W.

Mayo Clinic

Pacing and Clinical Electrophysiology | May 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/pace.70306 | PMID 42206323 Get It

ABSTRACT Background Coronary artery (CA) injury from catheter ablation is an uncommon complication, but the risk is under‐recognized. The risk for CA injury significantly increases when a CA is within 3 mm of the site of ablation, but CA imaging to assess for CA proximity to ablation sites is not commonly performed in children prior to ablation. Objective The aim of the study was to assess CA proximity to potential ablation sites. Methods A retrospective review of all coronary computed tomography angiograms (CTAs) in pediatric patients <18 years of age at Mayo Clinic from 2017 through 2023 was conducted. The proximity of CAs to potential ablation sites in the coronary sinus and the appendage bases were measured. Results Seventy‐two CTAs in 67 patients >15 kg and <18 years old were included. Median age was 12 years, and median weight was 41 kg. In right dominant CA circulation, 23/36 (64%) had a CA within 3 mm of the coronary sinus. In left and co‐dominant CA circulation, 26/26 (100%) had a CA within 3 mm of the coronary sinus. The right CA was within 3 mm of the appendage base in 49/69 (71%). The circumflex CA was within 3 mm of the appendage base in 50/68 (74%). Conclusion Most pediatric patients have a CA ≤ 3 mm from potential ablation sites in the coronary sinus and base of the appendages. Precautions should be taken to avoid CA damage before performing catheter ablation in these areas.
Association of drug industry payments to oncologists and use of guideline-preferred cancer treatments.
Augello, Patrick, Abdelaziz, Abdullah, Guzman, Gabrielle , Galanter, Nina, Chakraborty, Nirjhar , Klimchuk, Maria , Alsamarai, Susan, Rajkumar, S. Vincent, Bach, Peter B. , Gönen, Mithat , Mitchell, Aaron Philip , Winn, Aaron N. , Augello, Patrick , Meza, Akriti Mishra , Abdelaziz, Abdullah , Galanter, Nina , Dusetzina, Stacie B.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 11059-11059

10.1200/jco.2026.44.16_suppl.11059 Get It

11059 Background: Payments from the drug industry to oncologists are common and influence physicians’ prescribing decisions. However, whether payments affect the likelihood that patients receive optimal cancer treatment has not been assessed. Methods: This was a population-based cohort study. We used fee-for-service Medicare claims to identify patients with incident cancer diagnosis (new cancer diagnosis code after >= 1 year with no cancer diagnosis codes) from 2014-2020. We used National Comprehensive Cancer Network (NCCN) Guidelines to identify treatment scenarios (e.g., metastatic melanoma, stage III colon adjuvant therapy) with variation in the clinical benefit among recommended treatment options. The patient cohort corresponding to each scenario was identified using claims. We used NCCN Guidelines to identify the “optimal” treatment for each scenario (defined as the designated “preferred” treatment, with NCCN Evidence Blocks scores used for tiebreaks) at each time point across the study period. The primary outcome was whether a patient received the treatment that was, as of their diagnosis date, the optimal treatment for their cancer (vs. any non-optimal treatment). The primary exposure[s] were whether a patient’s medical oncologist received personal (“general”) payments (source: linked Open Payments data) related to 1) optimal treatment or 2) any non-optimal treatment, during the year prior to the patient’s cancer diagnosis. We fit Poisson-family generalized estimating equations, with physician-level clustering and adjustment for scenario, year, and patient characteristics, to estimate the relative risk (RR) of optimal treatment. Results: There were 14 clinical scenarios comprising 15,835 patients. There were 3,429 (21.7%) patients whose oncologist received payment for the optimal treatment, 4,891 (30.9%) for non-optimal payments, and 1,993 (12.6%) to both payment types. Oncologist receipt of payment for optimal treatment was associated with a greater likelihood (RR=1.07, 95%CI:1.01-1.13), and payment for non-optimal treatment was associated with lower likelihood (RR= 0.94, 95%CI:0.89-0.98) of patients receiving optimal treatment. Associations became stronger as payment dollar value increased; for optimal payments ≥$10,000, RR=1.26 (95%CI:1.02-1.57), and for non-optimal payments ≥$10,000, RR=0.70 (95%CI: 0.49-1.00). An estimated 41.6% of unexposed patients received optimal treatment; versus 52.6%, 29.3%, and 33.8% among patients exposed to ≥$10,000 of payments for optimal treatment only, ≥$10,000 non-optimal payments only, and ≥$10,000 of both payment types, respectively. Conclusions: Industry payments related to the optimal cancer treatment were associated with increased use of the optimal treatment. However, payments related to non-optimal treatments were more common and were associated with decreased use of optimal treatment.